Understanding the Science Behind the Clinical Data for HCV Emerging Therapies

Effective management of Chronic Hepatitis C Virus (HCV) continues to pose a challenge for healthcare practitioners. The discovery, development and availability of direct-acting antiviral agents (DAAs) offers new treatment options and the possibility of improved outcomes for newly diagnosed patients as well as those who have experienced a relapse or failed to respond to previous treatment. However, their use introduces new challenges and adds to the complexity of HCV treatment and care. With rapid advancements in the field and new agents offering potential improvements in outcomes, shorter treatment durations, and unique adverse event profiles, clinicians must stay informed of the evolving data in order to counsel patients appropriately—in particular, those who may wish to discuss the benefits and risks of initiating therapy now vs delaying treatment.

This roundtable discussion among leading experts in HCV will be recorded immediately following the 2013 EASL meeting in Amsterdam, Netherlands and will explore some of the most recent findings and address the evidence-based clinical application of these data for HCV patients.

 Learning Objectives include:

* Evaluate evidence-based clinical data on the safety and efficacy of investigational regimens currently being studiedto treat HCV to assist in current and future clinical decision-making.

* Identify the different mechanisms of action of the various DAA classes and describe the rationale for combinations under investigation for different patient groups.

* Evaluate emerging data on current and new combination therapies in subpopulations of HCV patients, including those with cirrhosis, co-infection, or transplant.

CME credit is available. To register, visit www.hcvwebinar.com, or call 1-855-276-6855.




Share this Post